ArticleFrontiers in immunology2025
Axl inhibitor-mediated reprogramming of the myeloid compartment of the
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Single-Cell RNA-Sequencing Reveals Tumor Microenvironment Composition and Prior Therapy Modulate Response to Axl Inhibition.Cellular and molecular bioengineering · 2026Article
- Development of a Synthetic Hydrogel to Foster Microvascularization of an Endometriosis Microphysiological System.Advanced healthcare materials · 2026Article
- Integrated single-cell and bulk RNA sequencing analyses identify a myeloid state-related gene signature for molecular subtyping in stomach adenocarcinoma.Frontiers in immunology · 2026Article
- Targeted Therapies Modulating Mesenchymal-Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axl, a member of the receptor tyrosine kinase family comprised of Tyro3, Axl, and MerTK, is a promising cancer therapeutic target actively under clinical investigation. Axl is understood to be a dual target in cancer to (1) prevent tumor cell growth and invasion and (2) potentiate anti-tumor immunity. This immunity is characterized by myeloid cell activation and downstream recruitment and activation of anti-tumor T cells. However, the ways by which Axl inhibition promotes myeloid cell activation in the tumor microenvironment are incompletely understood. There is thus a need to understand the effects of Axl inhibition on myeloid cells in the context of the broader tumor microenvironment. Here, we developed a human
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.